HomeAI · summaries
Storia in 17 fonti
Nova caneta contra obesidade leva pacientes a perder até 32 kg em estudo de fase 3 | G1
Retatrutida, molécula da Eli Lilly ainda em investigação, mostrou perda média de 28,3% do peso corporal em 80 semanas; resultado se aproxima de índices observados em cirurgias bariátricas.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Retatrutide induces ‘impressive’ weight loss of up to 28.3% for adults with obesity
A once-weekly triple receptor agonist conferred up to 28.3% weight loss at 80 weeks for adults with overweight or obesity, according to topline results from a phase 3 trial. As…
- ·
nbcnews.com
People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
The results — the most weight loss ever seen in a medication trial — put the drug’s effectiveness on par with bariatric surgery.
